COMS-1 Phase III Randomized Trial of Enucleation
vs I-125 Plaque Radiotherapy in Patients With Medium-Size Choroidal Melanoma
Accrual: At least 2,000 patients with medium-size tumors will
be required, and at least 1,000 patients with large melanomas will be required.
Accrual objectives may be revised as intermediate data are analyzed and
as data from external sources become available. The target accrual of patients
with small tumors was met as of November 1989; as of July 1995, accrual
of large tumors was completed.
Chairperson: Stuart L. Fine. Lead organization: Collaborative Ocular
Melanoma Study. Telephone: (215) 662-8675. Age range: 21 and over.
EORTC-88941 Phase II Pilot Study of IFN-A
and BLEO/VCR/CCNU/ DTIC (BOLD) in Metastatic Malignant Uveal Melanoma
Accrual: Up to 50 patients will be entered within three years. If no
response is observed in the first 19 patients, the study will stop.
Chairperson: Seppo Pyrhonen. Lead organization: EORTC Ophthalmic Oncology
Group. Telephone: 358-9-4713364 (Finland). Age range: 18 to 70.
SJCRH-RET-3, NCI-H96-0935 Phase II Study
of Carboplatin and Vincristine for Pediatric Retinoblastoma
Accrual: A total of 25 patients will be entered over 4.5 years if there
are at least 12 responses at the week 24 evaluation in the first 16 patients.
Chairperson: Charles Benton Pratt, III. Lead organization: St. Jude
Children’s Research Hospital. Telephone: (901) 495-3442. Age range: under
3.
MSKCC-95040, NCI-V95-0710 Phase II Study
of Adjuvant CBDCA for Intraocular Retinoblastoma Followed by CDDP/CTX/VCR/
VP-16 for Residual Vitreous Disease
Accrual: 25 patients/stratum will be entered over 5-6 years.
Chairperson: Ira Jay Dunkel. Lead organization: Memorial Sloan-Kettering
Cancer Center. Telephone: (212) 639-2153. Age range: under 18.
Legend for Abbreviations:
COMS = Collaborative Ocular Melanoma Study
EORTC = European Organization for Research on Treatment of Cancer
MSKCC = Memorial Sloan-Kettering Cancer Center
SJCRH = St. Jude Children’s Research Hospital